|
Match
|
Document |
Document Title |
|
|
7323461 |
Use of methylene blue and related compounds to prevent or reverse an exaggerated hemodynamic reaction
The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans....
|
|
|
7320985 |
Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
A method for stabilizing an arylcarboxylic acid, which comprises adding a heterocyclic base to the arylcarboxylic acid or a pharmacologically acceptable salt thereof, a stabilizer thereof and an...
|
|
|
7148216 |
Combinations of drugs for the treatment of neoplastic disorders
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts...
|
|
|
7008934 |
Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active...
|
|
|
6995154 |
Heterocyclic topoisomerase poisons
The invention provides compounds of formula I:
wherein R 1 to R 5 have any of the values defined in the specification, as well as pharmaceutically acceptable salts of the compounds,...
|
|
|
6982262 |
Combination of cyamemazine and an atypical neuroleptic
The present invention relates to the combination of cyamemazine and an atypical neuroleptic, or a pharmaceutically acceptable salt thereof, and to the use thereof in the treatment of schizophrenia,...
|
|
|
6897199 |
Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their...
|
|
|
6846816 |
Combinations of drugs for the treatment of neoplastic disorders
The invention features a method for treating a patient having a cancer or other neoplasm by administering to the patient two compounds simultaneously or within 14 days of each other in amounts...
|
|
|
6790463 |
Uses of targeted oxidative therapeutic formulation in arteriosclerosis
The use of a pharmaceutical formulation in treating coronary arteriosclerosis and a two-component pharmaceutical formulation. The pharmaceutical formulation contains peroxidic species or reaction...
|
|
|
6780871 |
Methods and compositions for treating addiction disorders
A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is...
|
|
|
6747024 |
Heterocyclic compounds and their use as medicines
The present invention relates to new heterocyclic derivatives having an inhibitory activity on calpains and/or a trapping activity on reactive oxygen species, of formula in which A, X, Y, R1, R...
|
|
|
6703401 |
Compounds, their preparation and use
The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the...
|
|
|
6686388 |
Regulators of the hedgehog pathway, compositions and uses related thereto
The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function...
|
|
|
6599532 |
Osmotic device containing alprazolam and an antipsychotic agent
The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A...
|
|
|
6593347 |
Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated...
|
|
|
6583138 |
Heterocyclic-ring condensed benzothiazine compound
The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate....
|
|
|
6569853 |
Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
The invention features a method for treating a patient having a cancer or other neoplasm, by administering to the patient (i) chlorpromazine or a metabolite or analog thereof; and (ii) pentamidine...
|
|
|
6566389 |
Therapeutic uses of melatonin
A method for treating or preventing symptoms of tardive dyskensia comprises administering melatonin to patient exhibiting or liable to develop such symptoms. The melatonin is administered in an...
|
|
|
6534500 |
Use of cyamemazine in the treatment of abrupt benzodiazephine withdrawal
The present invention relates to the use of cyamamazine, or the pharmaceutically acceptable salts thereof, in the treatment of abrupt benzodiazepine withdrawal.
|
|
|
6509335 |
Benzoxazinoes/benzothiazinones as serine protease inhibitors
This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also...
|
|
|
6492332 |
Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
This invention relates to a method of inhibiting tumor cell adhesion, pain, and inflammation at a wound during a surgical procedure by delivering an irrigation solution containing a tumor cell...
|
|
|
6482822 |
N-(iminomethyl)amines derivatives, their preparation, their use as medicines and compositions containing them
The invention concerns novel N-(iminomethyl)amine derivatives comprising in their skeleton the aminophenylamine, oxodiphenylamine, carbazole, phenazine, phenoxazine or oxodiphenyl motif, their use...
|
|
|
6346529 |
Antiviral therapy using thiazine dyes
A method for using thiazine dyes, especially methylene blue, alone or in combination with low levels of light, to selectively inactivate or inhibit intracellular replication of specific viruses,...
|
|
|
6172058 |
Compounds with pharmaceutical properties
A pharmaceutical compound of the formula ##STR1## in which R 1 is C 1 -10 alkyl, C 2 -10 alkenyl, C 2 -10 alkynyl, C 3 -10 cycloalkyl, C 3 -10 cycloalkyl-C 1 -10 alkyl, C 3 -10 cycloalkyl-C 2 -10...
|
|
|
6159966 |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
A compound of formula (I) ##STR1## its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates, wherein R 3 , R 4 , R...
|
|
|
6140324 |
Use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine to treat motion sickness
The present invention relates to the use of a tachykinin antagonist and a muscarinic antagonist and/or an antihistamine for the treatment or prevention of motion sickness. There is also provided...
|
|
|
6121278 |
Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
A compound of formula I: ##STR1## or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof, wherein: Y represents the atoms necessary...
|
|
|
6075020 |
Method of regulating immune function
Disclosed herein is a method of treating an immune system dysfunction in a mammal by administering a prolactin reducer and a prolactin enhancer at a predetermined time or times.
|
|
|
5994349 |
3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives
Phenothiazines of the formula: ##STR1## where R 1 is H or --COOR, where R is selected from the group consisting of branched or unbranched alkyl groups containing from 1 to 4 carbon atoms, and...
|
|
|
5925634 |
Use of ibogaine for treating neuropathic pain
This invention discloses that ibogaine, a plant derivative, can be used safely to treat neuropathic pain (i.e, pain which does not respond conventionally to opiate drugs such as morphine). Ibogaine...
|
|
|
5869479 |
Treatment of upper airway allergic responses
Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H 1 receptor antagonist; together with (b) a sufficient amount of a...
|
|
|
5863912 |
Method of treatment of hormone-unresponsive metastiatic prostate cancer
Prostate cancer particularly hormone-unresponsive metastatic prostate cancer, is treated by cyclophosphamide or other normally substantially inactive agent. Potentiation of the anti-cancer activity...
|
|
|
5861394 |
Use of N-substituted phenothiazines
The invention relates to the use of N-substituted phenothiazines for the production of medicaments for the treatment of cerebral disorders. The invention likewise relates to novel active compounds...
|
|
|
5834465 |
Treatment with combined NMDA and non-NMDA antagonists to reduce excitotoxic CNS damage
This invention involves a pharmaceutical mixture for preventing or reducing excitotoxic brain damage caused by hypoxia/ischemia (such as stroke) and various other factors. This mixture comprises an...
|
|
|
5830902 |
Quinuclidine derivative having tricyclic hetero condensed ring
A quinuclidine derivative represented by the following general formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, which has strong squalene synthase...
|
|
|
5767130 |
Use of kainic acid antagonists to prevent toxic side effects of NMDA antagonists
This invention discloses that kainic acid receptor antagonists (KA antagonists) can act as "safener" agents to reduce or prevent adverse side effects caused by NMDA antagonists. NMDA antagonists...
|
|
|
5663167 |
Antipsychotic composition and method of treatment
A method for treating a serious psychotic mental illness includes the step of administering to a patient in need of such treatment a combination of (i) an α 2 -adrenergic receptor antagonist and...
|
|
|
5629307 |
Use of ibogaine in reducing excitotoxic brain damage
This invention discloses that ibogaine, a plant derivative, can be used as a safe NMDA antagonist at relatively high dosages (including dosages high enough to cause hallucinations), to reduce or...
|
|
|
5616580 |
Pharmacological composition for preventing neurotoxic side effects of NMDA antagonists
This invention discloses mixtures of NMDA antagonists and anti-cholinergic agents, which can be used to prevent excitotoxic damage in the central nervous system or for anesthetic purposes in human...
|
|
|
5597819 |
Phenothiazine cytokine inhibitors
New benzothiazine derivatives corresponding to the general formula I: ##STR1## in which: X represents halogen, n represents 0, 1, or 2, B represents the following formula: ##STR2## in which:...
|
|
|
5543407 |
Preparation and application of scopolamine and chlorpromazine as a drug-withdrawal agent
An empirical efficacy appears in the drug-withdrawal treatment of drug dependence with a novel drug-withdrawal scopolamine agent(DSA) which contains scopolamine hydrobromide as a subsidiary...
|
|
|
5502049 |
Use of phenothiazine derivatives in the treatment of ischaemia and/or hypoxia
This invention relates to a novel therapeutical use of phenzothiazine derivatives of general formula (I), ##STR1## wherein R is a straight or branched chain C 1 -5 alkyl radical, and R 1 and R 2 ,...
|
|
|
5496818 |
Stable emulsion suitable for pharmaceutical administration, the production thereof and emulsion for pharmaceutical use
A stable active substance emulsion of the oil-in-water type with a phospholipid as emulsifier is described, where the active substance dissolved in the lipid phase has one or more basic groups, is...
|
|
|
5474990 |
Barbiturates as safening agents in conjunction with NMDA antagonists
Certain barbiturates have been shown to completely prevent the neurotoxic injury to cerebrocortical neurons that can be caused by NMDA antagonists. The use of barbiturates as "safening agents"...
|
|
|
5432168 |
Method of treatment of hormone-unresponsive metastatic prostate cancer
Prostate cancer particularly hormone-unresponsive metastatic prostate cancer, is treated by cyclophosphamide or other normally substantially inactive agent. Potentiation of the anti-cancer activity...
|
|
|
5372801 |
Biological stain composition, method of preparation and method of use for delineation of epithelial cancer
A biological stain composition contains toluidine blue O and a pharmaceutically acceptable oxidizing agent to convert any leuco toluidine blue O to the chromo form. A dry composition for preparing...
|
|
|
5322847 |
Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
A series of imidazo[4,5-c]pyridines which inhibit platelet activating factor (PAF) and also block leukotriene D4 receptors are useful in treating asthma, arthritis, psoriasis, gastrointestinal...
|
|
|
5321026 |
Phenothiazine derivatives, their preparation and pharmaceutical compositions containing them
New phenothiazine derivatives of general formula (I) in which R represents 4- to 6-membered cycloalkyl, or represents --CH 2 R" in which R" is hydrogen, alkyl containing 1 to 5 carbon atoms,...
|
|
|
5298506 |
Use of guanylate cyclase inhibitors in the treatment of shock
The invention relates to the administration of guanylate cyclase inhibitors, such as methylene blue, for the treatment of septic shock, cardiogenic shock, hypovolemic shock, obstructive shock,...
|
|
|
5254595 |
Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
Aryloxypropanolaminotetralins with beta-antagonist activity of the formula ##STR1## wherein R is hydrogen, hydroxy or methoxy and Ar is an optionally substituted aromatic or heteroaromatic group,...
|